Italian opera superstar Luciano Pavarotti, who had surgery for pancreatic cancer in July 2006 and then was hospitalized this August 8 due to a high fever, will stay in the hospital for further testing related to his disease.

Pavarotti, 71, is now fever-free. Still, he will remain hospitalized so his cancer can be fully investigated.

At the time of Pavarotti's surgery, he had been planning to resume his farewell tour. But he has made no public appearances since this time.

Testing for oral cancer just got much easier -- a new method of testing for the disease will soon be available. The testing method can be done in a medical office and uses lab-on-a-chip microfluidic technology to determine a diagnosis. Furthermore, the test is fully automated and can be completed in a mere 10 minutes.

The test was developed at researchers at the University of Texas (Austin) with funding from the NIH. Here's how it works: Cells from the mouth are mixed with fluorescent marker proteins, illuminating any suspicious cells. Pretty ingenious, if you ask me. Now if we could only make other cancer screening as painless and quick ...

Join Living Beyond Breast Cancer (LBBC) for their next national teleconference, Follow-up Testing: What You Need to Know, from 12:00 p.m. to 1:30 p.m. Eastern Daylight Time (EDT) on Thursday, August 16. Virginia F. Borges, MD, of the University of Colorado Health Science Center, will answer your questions about follow-up testing after initial treatment, including:

• An overview of follow-up testing guidelines and insights into future tests
• Uses or limitations of screening tests
• Emotional impact of follow-up testing
• Routine follow-up tests for other health matters affected by treatment
• Creating a plan to monitor your overall health
• The role of follow-up tests for women with advanced (metastatic) breast cancer

Dr. Borges is an assistant professor of medicine at the University of Colorado Health Science Center. She specializes in the treatment of breast cancer, and her research interests include the study of new biologic therapies for breast cancer, development of cancer vaccines and improving the quality of life for people affected by breast cancer. In addition to her clinical practice and research efforts, Dr. Borges volunteers as a medical facilitator for Casting for Recovery.

After the presentation, Dr. Borges will answer questions

Living Beyond Breast Cancer will hold a free teleconference, Follow-up Testing: What You Need to Know, from 12:00 p.m. to 1:30 p.m. Eastern Daylight Time (EDT) on Thursday, August 16.

Speaker Virginia F. Borges, MD, will discuss follow-up testing after initial treatment, including follow-up testing guidelines, insights into future tests, the uses or limitations of screening tests and the emotional impact of follow-up testing. She also will explain the need for routine follow-up for other treatment-related health matters, creating a plan to monitor overall health and the role of follow-up tests for women with advanced (metastatic) breast cancer.

Dr. Borges is an assistant professor of medicine at the University of Colorado Health Science Center. Dr. Borges specializes in the treatment of breast cancer and her research interests include the study of new biologic therapies for breast cancer, development of cancer vaccines and improving the quality of life of people affected by breast cancer. In addition to her clinical practice and research efforts, Dr. Borges volunteers as a medical facilitator for Casting for Recovery.

This free program will feature a presentation by the speaker and a 45-minute question-and-answer session with participants. Participants can listen over the phone or use their computer.

To register, visit Living Beyond Breast Cancer's website at www.lbbc.org or call (610) 645-4567

The researchers don't seem to know why, but there is a decline in the number of women in the United States age 40 or older who have had mammograms over the last two years.

A study published in the journal Cancer says that during the period from 1987 to 2000, there was a steady increase in women receiving mammograms. They believe this to be somewhat responsible for the increase in breast cancer survival that occurred during that period. Supporting the phrase -- early detection saves lives.

They evaluate the trends in mammography use by a survey that is administered to 35,000 adults called the National Health Interview Survey. The current analysis focused on women who had mammograms in the last two years. The survey showed that in the year 2000, 70 percent of women reported they had a mammogram in the previous two years. In the year 2005, the number was down to 66 percent.

New hope may be an injection away for patients living with glioma, a terminal brain cancer that comes with a life expectancy of about 25 weeks post-diagnosis.

A new vaccine called Vitaspen is made by using tissue extracted from each person's cancerous tumor. The tissue is used as a unique footprint for the vaccine that targets destructive tumor tissue while sparing healthy tissue in the same region.

Vitaspen is only in the first stage of clinical human trials, but researchers are pleased with the promise of the new drug -- particularly the benefits trial participants are gaining form the treatment. They have reported no adverse side effects, and the drug has increased the overall survival rate.

Results of stage one trials will determine if the drug warrants stage two testing.

I never would have predicted it -- that a tooth could become a tool for dispensing medication. But the refinement of such a creation is actually in the works and before long, you may be asking not for a gold or decorative tooth but for one capable of doling out your drugs in the exact doses and at the right times.

Think about this:

Researchers from Europe and Israel are working right now on a tiny dispensing system called IntelliDrug. Their goal is to create parts small enough they can fit into a false tooth placed in the back of the mouth. The device will release a specific amount of medication at certain intervals so patients receive the proper dosage right on schedule.

This invention, crafted by an Israeli dentist, could pick up the slack for people who forget to take medicine and could save lives for those whose lives depend on scheduled drug therapy. It could also allow for better absorption of medication into the body.

The IntelliDrug device will deliver medicine directly into the bloodstream through the lining of the cheek around the mouth. Saliva, meanwhile, mixes with the drug and carries it throughout they body in a manner more efficient than just swallowing a pill every few hours.

While researchers hope to one day turn their device into a replacement tooth, the apparatus -- consisting of a stainless steel housing, a pump, custom valves, a microprocessor, batteries, and a reservoir for the drug pill -- currently comes in the form of a block the size of two teeth. It is strapped to the the side of teeth and hugs the inside of the cheek. The unit can be removed, and a technician can refill the drug reservoir, clean the unit, and change batteries when necessary.

Clinical trials on pigs are ongoing. Human testing is expected to begin by the end of the year.

A doctor found something suspicious when she read the results of the breast MRI I had on Friday. What she found is of unknown significance. This means something caught her attention. She just isn't sure what it is.

This doctor does know that whatever it is inside my right breast appears to be a low-risk something. But still, there's a concern looming in the air -- for her and for me.

I spoke with my oncologist about this concern, and he told me anything suspicious must be pursued by further testing. I'm thankful for that. He also said he expects that nothing actually significant will come of this. But if it does, it will have been caught early.

On Friday, I will report for further testing -- a mammogram and an ultrasound -- and then I will learn more about this unknown something that inhabits my breast, this something that takes me back more than two whole years when another something turned out to be what I feared more than anything. Breast cancer.

Living Beyond Breast Cancer (LBBC) is hosting a free educational teleconference for women affected by breast cancer, women at high risk for developing breast cancer and caregivers.

Breast Cancer Genetics: The Role of Genetic Tests and Family Risk Assessment will give the facts about genetic counseling and testing. Learn how the results could impact your health choices and your life.

Topics to be discussed:

• When and why to consider genetic testing
• Goals of genetic counseling and how it can help you understand your risk and test results
• Effectiveness of medical and surgical prevention methods
• Strategies for monitoring the health of women at risk for developing a second breast cancer or other cancers
• Ways to lessen anxiety about testing and communicate effectively with family members
• Laws that protect you from insurance and job discrimination

All LBBC teleconferences begin with brief speaker presentations followed by question and answer sessions with participants.

The teleconference will be held on Thursday, March 29, 2007. 12:00 p.m. - 1:30 p.m. EDT

Researchers have found that when cells become cancerous, they become 100 times more likely to genetically mutate than non-cancerous cells. This explains why tumor cells have so many mutations. Good news on the research front. But bad news on the treatment front -- because therapies that target a certain gene may be largely ineffective in controlling cancer.

"This is very bad news, because it means that cancer cells in a tumor will have mutations that protect them from therapeutics," says lead researcher Dr. Lawrence Loeb, professor of pathology and biochemistry at the University of Washington School of Medicine in Seattle, who presented his findings February 18 at the meeting of the American Association for the Advancement of Science in San Francisco.

Loeb says chemotherapy drugs target specific oncogenes -- genes that affect the malignancy of a cell -- but if cancer cells are mutator cells, then a single tumor may have cells with all sorts of oncogenes. And while chemotherapy may kill some cancerous cells, millions of others will live on.

It's not all bad news, though, says Loeb who believes this research may help doctors determine the stage and malignancy of tumors by testing the number of mutations. It may also help researchers understand what makes a cancer cell a mutator and how to slow the rate of mutation.

"The idea is that if you might normally get exposed to something in the environment at 20 years old that would give you cancer by age 55, then if we cut the mutation rate in half, you might not get cancer until age 90, and you may even die of something else before that," Loeb explained.

Canadian researcher Evangelos Michelakis, associate professor of medicine at the University of Alberta in Edmonton, has stumbled upon something quite remarkable -- a potentially new anti-cancer agent called dichloroacetate, or DCA.

DCA is nothing new -- it's long been used for treatment of rare metabolic disorders -- but using it to fight cancer puts an entirely new spin on the potential of this drug.

"This is one of the most exciting results I've ever had," Michelakis said. "But I can't be overenthusiastic until it works on a human."

Michelakis and his colleagues have successfully used DCA to shrink human lung, breast, and brain tumors in both lab rats and test tubes. And while this type of research may not ordinarily generate a lot of excitement, this specific study is creating a buzz because DCA has been safely used in humans for decades, without adverse side effects.

"One of the big concerns about drugs is that they can harm people but we already know this drug is safe," Michelakis says. "It doesn't even affect normal cells."

One of the fundamental premises of cancer biology is that mitochondria -- the energy producing units of cells -- are permanently damaged by cancer. What DCA does is revive the mitochondrial function, encouraging the death of cancer cells.

The overwhelming hope is that DCA will move right to human testing. But the overwhelming fear is that it will not -- because of economic reasons. There is no longer a patent on DCA so it is not owned by any one company. With little chance of one group making a large profit, there may be no incentive for pharmaceutical companies to invest in research.

Sadly, this drug -- that appears to work remarkably well -- may never benefit cancer patients. All because no one stands to make billions of dollars from it.

Canadian researchers have made an unexpected discovery in a molecule that appears to drastically boost the ability of standard drugs to kill breast cancer cells. Currently, the discovery has been confined to the lab -- but researchers hope the power of this molecule, the ANK peptide, can one day be used to counter drug resistance for many women with breast cancer.

Scientists from Queen's University say the ANK peptide, not a drug by itself, gives drugs like taxol and nocodazole more than triple the ability to kill breast cancer cells. One scientist says the process of enhancing drug effectiveness is much like adding flavor to coffee to make it taste better.

This is exciting news, but the results -- published Monday in the journal Cancer Research -- only apply to lab experiments at this point. Researchers must now proceed with testing the peptide-drug combination in lab mice. If successful, they will move on to human testing. The whole process could take years. But early results are so promising that application for a U.S. patent on the peptide has already been made.

According the medical experts, breast cancer patients can become resistant to some drugs depending on duration of treatment, dose of medication, and genetic makeup.

"This peptide would be able to give them another chance," said a researcher from this study. "For those who respond reasonably well, they will do even better; for those who don't respond to this drug treatment ... we greatly hope this will make the current drug more useful by extending its impact to a wider range of people, particularly those with a resistance problem."

There are sometimes silver linings to the darkest of cancer clouds. I know -- because I have the dark cloud of HER2 positive breast cancer hanging over my head. HER2 positive means the tumor removed from my breast was aggressive. It aggressively over-expressed a protein that accelerates tumor growth. And it led to a poor prognosis -- that might be considered a good one too.

You see, research on the whole HER2 issue is turning up some pretty powerful potions. Like Herceptin -- the drug that miraculously cuts recurrence upwards of 50 percent for positive women like me. I was a lucky recipient of this drug. And the pharmacist who mixed the drug for all 17 of my infusions tells me it's really a good thing I have this HER2 problem -- because the drugs created to attack the problem may just cure me of my disease.

So in an odd turnabout -- from bad luck to good fortune -- I am not so sad my tumor was aggressive. It means there are bonus treatments for me. And if my cancer comes back and Herceptin no longer works, there is another drug called Tykerb. And now the Army is leading its own breast cancer vaccination study. The focus -- HER2.

Early study results from Walter Reed Army Medical Center in Washington, D.C. suggest a 50 percent reduction in disease recurrence for HER2 positive women who receive a vaccination of AE37.

AE37 targets HER2 and boosts the body's immune system so it can battle the protein before it stimulates growth. It's similar to Herceptin, but the activity of AE37 stimulates a patient's own immune system to recognize the cancer target rather than interacting with the target directly.

Should the Food and Drug Administration decide to support this study, it will proceed to Phase 3 testing, which includes a much larger pool of participants.

The 1998 guidelines on breast cancer follow-up has been updated by the American Society of Clinical Oncology. They state the most reliable way for detecting a recurrence is to receive physical exams and educating patients on the symptoms of recurrence.

All women should perform monthly breast exams. Genetic counseling is recommended for high risk women, including those with Askhenazi Jewish heritage, family history of breast or ovarian cancer, or diagnosis of bilateral breast cancer in the patient or relative.

Study results show no survival advantage for intensive verses conservative surveillance. Complete blood counts (CBCs), liver function tests, imaging studies, and assessment of tumor markers are not recommended for routine surveillance.

Breast cancer can recur within 15 years of the initial diagnoses and beyond, surveillance is a lifelong process for breast cancer survivors.

At home screening may reduce deaths from bladder cancer in men over fifty years of age. Bladder cancer is diagnosed in as many as 60,000 individuals annually in the United States and is much more common in the elderly.

Cancer of the bladder has a high cure rate if detected early enough, however, the cure rate gets much lower if the cancer spreads and metastasizes to other parts of the body. One way to diagnose the disease is to detect microscopic amounts of blood in the urine.

A trial was conducted including 1,575 men who did not have bladder cancer and were over fifty. The men underwent home screening with the use of small strips of a paper-like substance, called reagent strips. A little over 8 percent of patients who underwent screening were diagnosed with bladder cancer. At fourteen years follow-up, there were no deaths from bladder cancer among the men who underwent home screening compared with 20 percent among men who had not undergone screening.

The researchers conclude that at-home screening could indeed save lives because of early detection of bladder cancer.